SK biotek (SKBT), an SK pharmteco company, is a global CDMO with ~ 360 m³ of capacity globally. With state-of-the-art facilities in Korea and Ireland specialising in the manufacturing cGMP API and Advanced Intermediates via Advance Synthesis, Continuous Flow Processing and High Containment, from grams to multi-tons across the full product lifecycle for global innovative pharmaceutical companies.
Our plants in Korea are the leading supplier of late phase and commercial pharmaceutical materials using continuous processing. Continuous Flow Processing has many potential advantages over traditional batch processing; it is not just greener, highly efficient, cost effective and regulatory supported; also has the capability to achieve low temperature reactions, hazardous reactions (Azide Reactions/Hydrogen Peroxide etc.), high pressure (300 ATM), high temperature reactions (600°) and catalytic reactions.
Our facility in Dublin, has been manufacturing API and Intermediates for almost 60 years. For over 30 years, Swords Campus has maintained its leadership in the development, scale-up and commercial manufacture of highly potent chemical intermediates and API. For the last 20 years, Swords Campus has been the launch manufacturing site and centre of excellence for APIs for one of the world’s leading pharmaceutical companies. With exceptional technical capabilities within R&D, with extensive experience in custom development from clinical phases to commercial launch, scale-up for products.
SK biotek Ireland can today offer multi-scale plants (from grams to 100s of kg) capable of handling material with Occupational Exposure Limit (OEL) ≤ 10 ng/m³.
This integrated facility combines manufacturing plants, R&D and QC laboratories within the same building. Through the implementation of strong safety compliance policy and adherence to high-quality and safety standards, Swords Campus has a proven track record as a reliable supplier of HPAPIs to multiple customers.